Lighting Intervention to Improve Sleep

Sponsor
Icahn School of Medicine at Mount Sinai (Other)
Overall Status
Recruiting
CT.gov ID
NCT05757414
Collaborator
(none)
50
1
1
27.5
1.8

Study Details

Study Description

Brief Summary

50 participants with Parkinson's disease will be recruited to complete actigraphy studies to assess sleep disturbances. For this, participants will wear an Actigraph for seven days. Thirty of these participants with sleep disturbance, will go on to receive a tailored lighting intervention (TLI) to assess the effect on sleep, fatigue, and circadian entrainment via urinary melatonin levels.

Condition or Disease Intervention/Treatment Phase
  • Device: Tailored Lighting Intervention (LIT)
  • Device: Actigraph
N/A

Detailed Description

Participants will undergo one week of baseline data collection using the actigraph and light meter and one night of an overnight urine collection. At the completion of the baseline week, the lighting intervention will be installed in the participants home. Participants will be exposed to the lighting intervention for 2 hours each morning after awakening for 4 weeks. During the last week of the lighting, participants will be asked to wear the actigraph and light meter again for 7 days and collect one overnight urine sample. Participants will complete questionnaires before and after the intervention to further assess its effects.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Dissecting Oligogenic Biomarkers in Parkinson Disease
Actual Study Start Date :
Nov 16, 2021
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tailored Lighting intervention (TLI)

The TLI will be performed for 2 hours each day over a 4-week period. During the last week of the lighting, participants will be asked to wear the actigraph and light meter again for 7 days

Device: Tailored Lighting Intervention (LIT)
The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.

Device: Actigraph
An actigraph is a wrist worn device that measures rest and activity patterns

Outcome Measures

Primary Outcome Measures

  1. Sleep Duration using Actigraph [at baseline for 7 days]

    Sleep duration will be calculated by the Actigraph software. A longer sleep duration would indicate an improvement.

  2. Sleep Duration using Actigraph [at Week 4 for 7 days]

    Sleep duration will be calculated by the Actigraph software. A longer sleep duration would indicate an improvement.

Secondary Outcome Measures

  1. Sleep Effeciency using Actigraph [at Baseline for 7 days]

    Sleep efficiency will be calculated by the Actigraph software. Sleep efficiency refers to the percentage of time a person sleeps, in relation to the amount of time a spent in bed. The percentage is calculated by dividing actual sleep time by time in bed. A higher sleep efficiency indicates better sleep.

  2. Sleep Effeciency using Actigraph [at Week 4 for 7 days]

    Sleep efficiency will be calculated by the Actigraph software. Sleep efficiency refers to the percentage of time a person sleeps, in relation to the amount of time a spent in bed. The percentage is calculated by dividing actual sleep time by time in bed. A higher sleep efficiency indicates better sleep.

  3. Urine melatonin levels [at Baseline]

    Melatonin levels will be assess from overnight urine collection

  4. Urine melatonin levels [at Week 4]

    Melatonin levels will be assess from overnight urine collection

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of Parkinson's disease and

  • Difficulties with sleep or cognition

Exclusion Criteria:
  • There is no exclusion criteria

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mount Sinai Beth Israel New York New York United States 10003

Sponsors and Collaborators

  • Icahn School of Medicine at Mount Sinai

Investigators

  • Principal Investigator: Rachel Saunders-Pullman, Mount Sinai Beth Israel

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rachel Saunders-Pullman, Professor, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT05757414
Other Study ID Numbers:
  • STUDY-19-00185
First Posted:
Mar 7, 2023
Last Update Posted:
Mar 7, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 7, 2023